Rapid Micro Biosystems Secures $45 Million Loan Facility with Trinity Capital

Rapid Micro Biosystems secured a $45 million term loan facility with Trinity Capital, with an initial $20 million draw and potential for an additional $25 million. The loan has a 36-month interest-only period and an 11.5% annual floating interest rate. Funds will support commercial expansion and manufacturing efficiencies. The loan provides flexibility and reduces the immediate cash burden on the company, allowing for strategic investments without pressure.

Lexington, Mass., Aug. 12, 2025 – Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. (Nasdaq: TRIN). The loan facility, which includes four tranches, provides the company with a robust financial foundation to support its strategic initiatives.

The initial tranche of $20 million was drawn upon closing, with access to an additional $25 million available based on specific commercial and operational milestones. The loan facility has a five-year term, featuring an interest-only period of 36 months and an annual floating interest rate of 11.5%. This structure offers flexibility and reduces immediate cash burden, allowing Rapid Micro to focus on strategic investments without undue financial pressure.

The proceeds from this facility will be used for general corporate purposes, including supporting the continued global commercial expansion of the Growth Direct system and enhancing manufacturing efficiencies. The Growth Direct system, an innovative automation platform for microbial quality control (MQC) testing, aims to improve data integrity and accuracy, thus accelerating the manufacturing process and ensuring the safety and consistency of healthcare products.

Rapid Micro’s President and CEO, Robert Spignesi, expressed satisfaction with the terms of the loan facility, stating, “This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value.”

The loan facility, which includes customary representations, warranties, covenants, and events of default, does not require the company to maintain a specified level of revenues or cash resources. This flexibility allows Rapid Micro to focus on its core business objectives without additional financial constraints.

Rapid Micro Biosystems is an innovative life sciences technology company that provides mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products. The company’s flagship Growth Direct system automates and modernizes antiquated MQC testing workflows, bringing quality control labs to the manufacturing floor.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s newly-announced term loan facility, including the planned use of proceeds therefor and the intended benefits thereof.

[1] https://www.globenewswire.com/news-release/2025/08/12/3131512/33206/en/Rapid-Micro-Biosystems-Enters-into-Five-Year-45-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html